The coronavirus disease pandemic has impacted all areas of daily life, including medical care. The treatment of patients with lung cancer during this crisis is challenging [23, 24]. On the one hand, patients have a risk of death from cancer, which is increased if radical surgery is delayed. On the other hand, the risk of death or of serious complications from coronavirus disease and the higher lethality of the infection in immunocompromised patients have to be weighed in relation to the former. The Royal College of Surgeons of England [25] noted that patients with cancers with a high risk of progression without treatment should be operated on as resources, such as the capacity of intensive care units, permit. In some cases [10], neoadjuvant therapy may be used as a means of delaying surgery, although the risk of exposure to COVID-19 during clinic visits for chemotherapy or radiotherapy is still high.